Details of the Drug

General Information of Drug (ID: DMOFFAR)

Drug Name

Lucinactant

Synonyms

Surfaxin (TN)

Indication

Disease Entry	ICD 11	Status	REF
Congenital alveolar dysplasia	N.A.	Approved	[1]
Respiratory distress syndrome	CB00	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1/2	[3]
------------------------------------------------------------------------------------

Sequence

>Protein sequence for sinapultide
KLLLLKLLLLKLLLLKLLLLK

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C128H242N26O24
Canonical SMILES: CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)O)NC(=O)C(CCCCN)N.CC(=O)O
InChI: 1S/C126H238N26O22.C2H4O2/c1-69(2)53-90(137-106(153)85(132)43-33-38-48-127)114(161)145-98(61-77(17)18)122(169)149-99(62-78(19)20)118(165)141-91(54-70(3)4)110(157)133-86(44-34-39-49-128)107(154)138-95(58-74(11)12)115(162)146-103(66-82(27)28)123(170)150-100(63-79(21)22)119(166)142-92(55-71(5)6)111(158)134-87(45-35-40-50-129)108(155)139-96(59-75(13)14)116(163)147-104(67-83(29)30)124(171)151-101(64-80(23)24)120(167)143-93(56-72(7)8)112(159)135-88(46-36-41-51-130)109(156)140-97(60-76(15)16)117(164)148-105(68-84(31)32)125(172)152-102(65-81(25)26)121(168)144-94(57-73(9)10)113(160)136-89(126(173)174)47-37-42-52-131;1-2(3)4/h69-105H,33-68,127-132H2,1-32H3,(H,133,157)(H,134,158)(H,135,159)(H,136,160)(H,137,153)(H,138,154)(H,139,155)(H,140,156)(H,141,165)(H,142,166)(H,143,167)(H,144,168)(H,145,161)(H,146,162)(H,147,163)(H,148,164)(H,149,169)(H,150,170)(H,151,171)(H,152,172)(H,173,174);1H3,(H,3,4)/t85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-;/m0./s1
InChIKey: OSPNFKYGOFXGBX-YWWKUQGPSA-N

Cross-matching ID

Repurposed Drugs (RPD)

References

1	Lucinactant FDA Label
2	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3	The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19